Want to see KLRS full AI Analyst Report?
Top Page
Kalaris Therapeutics
(NASDAQ:KLRS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▼(-28.57% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (pre-revenue, large ongoing losses and negative free cash flow, with equity erosion), partially offset by low leverage. Technicals are mixed with longer-term downtrend signals, while valuation is constrained by negative earnings and no dividend. Corporate events provide a moderate positive tilt due to encouraging early clinical results and strengthened financial/governance leadership.
Positive Factors
Promising TH103 clinical differentiation
Positive Phase 1a results support the possibility that TH103 can deliver meaningful clinical benefit in neovascular AMD while offering longer treatment durability. If confirmed in later trials, this profile could differentiate the candidate, improve its commercial appeal, and strengthen Kalaris’s strategic position.
Negative Factors
No commercial revenue base
The absence of commercial revenue means Kalaris currently lacks an operating income stream to support research, development, and corporate expenses. Its financial outlook therefore remains dependent on clinical progress and external financing until a candidate can be approved, launched, and converted into recurring sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising TH103 clinical differentiation
Positive Phase 1a results support the possibility that TH103 can deliver meaningful clinical benefit in neovascular AMD while offering longer treatment durability. If confirmed in later trials, this profile could differentiate the candidate, improve its commercial appeal, and strengthen Kalaris’s strategic position.
Read all positive factors
Kalaris Therapeutics (KLRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.34M
Dividend YieldN/A
Average Volume (3M)61.02K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth73.44%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.02
Shares Outstanding23,804,981
10 Day Avg. Volume76,634
30 Day Avg. Volume61,016
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside269.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.02
Revenue Forecast (FY)N/A
Kalaris Therapeutics Business Overview & Revenue Model
Company Description
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEG...
How the Company Makes Money
Kalaris Therapeutics does not appear to generate recurring revenue from commercialized products; its revenue model is typical of a clinical-stage biotech. Primary funding sources are expected to include capital raising (e.g., issuing equity and/or...
Kalaris Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -20.00K | -13.00K | 0.00 | 0.00 | 0.00 | -1.12M |
| EBITDA | -45.10M | -41.98M | -58.77M | -14.01M | -15.25M | -169.84M |
| Net Income | -44.26M | -43.44M | -58.77M | -14.70M | -15.48M | -171.96M |
Balance Sheet | ||||||
| Total Assets | 99.54M | 121.74M | 118.55M | 3.33M | 3.90M | 286.59M |
| Cash, Cash Equivalents and Short-Term Investments | 93.54M | 117.98M | 118.29M | 3.17M | 3.06M | 248.12M |
| Total Debt | 1.40M | 1.45M | 0.00 | 0.00 | 3.25M | 30.07M |
| Total Liabilities | 41.87M | 42.92M | 5.24M | 48.35M | 34.17M | 61.33M |
| Stockholders Equity | 57.67M | 78.81M | 113.31M | -45.02M | -30.27M | 225.27M |
Cash Flow | ||||||
| Free Cash Flow | -45.63M | -43.18M | -67.70M | -14.13M | -9.78M | -106.34M |
| Operating Cash Flow | -45.43M | -42.98M | -67.70M | -14.13M | -9.78M | -106.32M |
| Investing Cash Flow | -49.90M | -19.72M | 95.00M | 0.00 | 0.00 | 185.98M |
| Financing Cash Flow | 50.08M | 159.61M | 21.00K | 14.24M | 12.78M | 232.00K |
Kalaris Therapeutics Technical Analysis
Negative
4.20
Price Trends
3.71
Negative
4.17
Negative
6.18
Negative
Market Momentum
-0.26
Positive
26.28
Positive
8.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Negative. The current price of 4.2 is above the 20-day moving average (MA) of 3.34, above the 50-day MA of 3.71, and below the 200-day MA of 6.18, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 26.28 is Positive, neither overbought nor oversold. The STOCH value of 8.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLRS.
Kalaris Therapeutics Risk Analysis
Kalaris Therapeutics disclosed 74 risk factors in its most recent earnings report. Kalaris Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kalaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.73B | -22.63 | -273.23% | ― | ― | -10.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.02B | -9.04 | -37.99% | ― | -27.15% | 23.10% | |
48 Neutral | $63.34M | -1.43 | -71.71% | ― | ― | 73.44% | |
45 Neutral | $182.31M | -1.19 | -181.73% | ― | -64.32% | 25.83% | |
43 Neutral | $34.60M | -1.38 | -60.32% | ― | ― | 71.26% | |
42 Neutral | $104.13M | -2.31 | -94.14% | ― | -0.11% | -13.99% |
* Healthcare Sector Average
KLRS
Kalaris Therapeutics
2.89
-3.18
-52.39%
CHRS
Coherus Biosciences
1.21
-0.41
-25.31%
NKTR
Nektar Therapeutics
60.55
1.70
2.88%
CLLS
Cellectis SA
1.51
-1.78
-54.10%
MCRB
Seres Therapeutics
3.35
-17.15
-83.66%
KOD
Kodiak Sciences
94.80
79.04
501.52%
Kalaris Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Kalaris Therapeutics Strengthens Financial Leadership With New CFO
Positive
Jul 20, 2026
On July 16, 2026, Kalaris Therapeutics appointed veteran biotech equity research analyst Liisa Bayko as Chief Financial Officer, Treasurer, and principal financial officer, effective July 20, 2026, with a compensation package combining salary, per...
Business Operations and StrategyProduct-Related Announcements
Kalaris Therapeutics reports positive Phase 1a TH103 results
Positive
Jul 17, 2026
On July 17, 2026, Kalaris Therapeutics reported additional positive results from expanded cohorts in its Phase 1a single ascending dose trial of TH103 in treatment-naïve neovascular AMD patients, reinforcing earlier findings of robust structu...
Executive/Board ChangesRegulatory Filings and Compliance
Kalaris Therapeutics Announces Board and Audit Committee Changes
Positive
Jul 6, 2026
On July 3, 2026, Kalaris Therapeutics announced that director Morana Jovan-Embiricos, Ph.D., resigned from its board and Audit Committee, with the company noting her departure was not due to any disagreement over operations, policies or practices....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.